Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients.

Bickel WK, Amass L, Crean JP, Badger GJ.

Psychopharmacology (Berl). 1999 Sep;146(2):111-8.

PMID:
10525745
2.
3.

A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence.

Petry NM, Bickel WK, Badger GJ.

Clin Pharmacol Ther. 1999 Sep;66(3):306-14.

PMID:
10511067
4.

Alternate-day dosing during buprenorphine treatment of opioid dependence.

Amass L, Bickel WK, Higgins ST, Badger GJ.

Life Sci. 1994;54(17):1215-28.

PMID:
8164503
5.

Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans.

Amass L, Bickel WK, Crean JP, Blake J, Higgins ST.

Psychopharmacology (Berl). 1998 Apr;136(3):217-25.

PMID:
9566806
6.

Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.

Correia CJ, Walsh SL, Bigelow GE, Strain EC.

Psychopharmacology (Berl). 2006 Dec;189(3):297-306. Epub 2006 Sep 30.

PMID:
17013637
7.
8.

Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine.

Lopatko OV, White JM, Huber A, Ling W.

Drug Alcohol Depend. 2003 Apr 1;69(3):317-22.

PMID:
12633918
9.

Thrice-weekly versus daily buprenorphine maintenance.

Schottenfeld RS, Pakes J, O'Connor P, Chawarski M, Oliveto A, Kosten TR.

Biol Psychiatry. 2000 Jun 15;47(12):1072-9.

PMID:
10862807
10.

Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet.

Amass L, Kamien JB, Mikulich SK.

Drug Alcohol Depend. 2000 Feb 1;58(1-2):143-52.

PMID:
10669065
11.

Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients.

Eissenberg T, Johnson RE, Bigelow GE, Walsh SL, Liebson IA, Strain EC, Stitzer ML.

Drug Alcohol Depend. 1997 Apr 14;45(1-2):81-91.

PMID:
9179510
12.

Limits to buprenorphine dosing: a comparison between quintuple and sextuple the maintenance dose every 5 days.

Gross A, Jacobs EA, Petry NM, Badger GJ, Bickel WK.

Drug Alcohol Depend. 2001 Sep 1;64(1):111-6.

PMID:
11470347
13.

Plasma concentrations of buprenorphine 24 to 72 hours after dosing.

Chawarski MC, Schottenfeld RS, O'Connor PG, Pakes J.

Drug Alcohol Depend. 1999 Jun 1;55(1-2):157-63.

PMID:
10402160
14.

Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.

Marsch LA, Bickel WK, Badger GJ, Jacobs EA.

Drug Alcohol Depend. 2005 Feb 14;77(2):195-204.

PMID:
15664721
15.

Effects of buprenorphine/naloxone in opioid-dependent humans.

Stoller KB, Bigelow GE, Walsh SL, Strain EC.

Psychopharmacology (Berl). 2001 Mar;154(3):230-42.

PMID:
11351930
16.

Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.

Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN.

Drug Alcohol Depend. 1998 Mar 1;50(1):1-8.

PMID:
9589267
17.

Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users.

Strain EC, Stitzer ML, Liebson IA, Bigelow GE.

Psychopharmacology (Berl). 1994 Dec;116(4):401-6.

PMID:
7701040
18.

Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans.

Schuh KJ, Walsh SL, Stitzer ML.

Psychopharmacology (Berl). 1999 Jul;145(2):162-74.

PMID:
10463317
19.

Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients.

Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C.

Addiction. 2003 Apr;98(4):441-52.

PMID:
12653814
20.

Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.

Umbricht A, Hoover DR, Tucker MJ, Leslie JM, Chaisson RE, Preston KL.

Drug Alcohol Depend. 2003 Apr 1;69(3):263-72.

PMID:
12633912
Items per page

Supplemental Content

Write to the Help Desk